The past,present,and future of radiotherapy for stage IV non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2018.01.006
- VernacularTitle:Ⅳ期NSCLC放疗的回顾与展望
- Author:
Bing LU
1
;
Shengfa SU
;
Zhixu HE
Author Information
1. 贵州医科大学附属医院/贵州省肿瘤医院胸部肿瘤科
- Keywords:
Carcinoma,non-small cell lung/two-dimensional radiotherapy;
Carcinoma,non-small cell lung/three-dimensional radiotherapy;
Treatment outcome
- From:
Chinese Journal of Radiation Oncology
2018;27(1):29-34
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of palliative care was definitive with two-dimensional radiotherapy for stage IV non-small cell lung cancer(NSCLC).However,theimpact of radiotherapy on survival was not well indicated,and some study resultsindicating prolonged survival were not accepted. Along with the advancesin three-dimensional radiotherapy (3DRT),wide application of comprehensive treatment,and the understanding of the association between different metastatic status and survival,prospective and retrospective studies have demonstrated that chemotherapy combined with 3DRT for primary tumor is more effective than chemoradiotherapy alone in improving symptoms and prolonging survival,especially for oligometastases of stage IV NSCLC.The dose to primary tumor is closely related to survival,and high-dose radiotherapy may be more likely to prolong survival. Further studies,however,areneeded to take into accountproblems such as thedose,timing,and technical selection of radiotherapy.
